Pharmacokinetic Profile of Rosemary Extract Supplement
Sponsor
CJ CheilJedang (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05931341
Collaborator
(none)
12
3
4
Study Details
Study Description
Brief Summary
This study is a clinical trial to observe changes in biomarkers in the blood at pre- and post-supplementation of rosemary extract in healthy adults.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Study Type:
Interventional
Anticipated Enrollment
:
12 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Investigator)
Primary Purpose:
Other
Official Title:
The Effects of Oral Adminstration of Softgel Capsule Including Rosemary Extract on Pharmacokinetic Profile in Healthy Adults
Anticipated Study Start Date
:
Aug 1, 2023
Anticipated Primary Completion Date
:
Nov 1, 2023
Anticipated Study Completion Date
:
Dec 1, 2023
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Dosage 1
|
Dietary Supplement: Rosemary extract
Softgel capsule including rosemary extract
|
| Experimental: Dosage 2
|
Dietary Supplement: Rosemary extract
Softgel capsule including rosemary extract
|
| Experimental: Dosage 3
|
Dietary Supplement: Rosemary extract
Softgel capsule including rosemary extract
|
Outcome Measures
Primary Outcome Measures
- Concentration in plasma [24 hours]
Eligibility Criteria
Criteria
Ages Eligible for Study:
25 Years
to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
-
Healthy subjects aged between 25 and 55 years
-
Non-smoker
-
Body Mass Index (BMI) between 20 and 30 kg/m2
Exclusion Criteria:
- Any history or presence of cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, endocrine, metabolic, hematological, neurologic, psychiatric, systemic or infectious disease
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- CJ CheilJedang
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
CJ CheilJedang
ClinicalTrials.gov Identifier:
NCT05931341
Other Study ID Numbers:
- CJFNT000001
First Posted:
Jul 5, 2023
Last Update Posted:
Jul 5, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No